ArticleCureus2025
Statin-Induced Immune-Mediated Necrotizing Myopathy: A Case Report of a Rare and Underrecognized Cause of Progressive Weakness.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Statin-induced necrotizing autoimmune myopathy is a rare immune-mediated process that leads to muscle necrosis and occurs following exposure to statin therapy. The diagnostic clue for this disorder stems from the development of a proximal muscle weakness associated with the elevation of creatine kinase levels in association with the use of statin medication. Management mainly includes discontinuation of the statin medication, pursuing a tissue diagnosis, and early initiation of immunosuppressive therapy to preserve and regain muscle strength. We present the case of a 54-year-old patient with statin-induced necrotizing autoimmune myopathy who developed proximal muscle weakness a few months after initiation of statin therapy, was positive for anti-HMGCR (anti-hydroxy-methyl-glutaryl coA reductase) autoantibodies, and had evidence of muscle necrosis with minimal cellular infiltration on muscle biopsy. A definitive diagnosis can often be made without biopsy in the presence of positive anti-HMGCR antibodies and a compatible clinical presentation, though biopsy remains valuable for seronegative or atypical cases. He was treated with immunosuppressive therapy using intravenous immunoglobulins and was noted to have a good response. This case report highlights the importance of early recognition of statin-related adverse effects that require urgent evaluation and timely therapy to preserve and improve the functional status of a patient.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.